Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children

PLoS One. 2013;8(1):e53772. doi: 10.1371/journal.pone.0053772. Epub 2013 Jan 22.


Background: The treatment of falciparum malaria poses unique challenges in settings where malaria transmission intensity is high because recurrent infections are common. These could be new infections, recrudescences, or a combination of the two. Though several African countries continue to use quinine as the second line treatment for patients with recurrent infections, there is little information on its efficacy when used for rescue therapy. Moreover, such practice goes against the World Health Organisation (WHO) recommendation to use combination therapy for uncomplicated malaria.

Methods: We conducted a nested, randomized, open label, three-arm clinical trial of rescue therapy in children 6-59 months old with recurrent malaria infection during 28 days post treatment with artemisinin combination treatment (ACT). Patients were randomly assigned to receive either quinine, artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHAPQ), and actively followed up for 28 days.

Findings: Among 220 patients enrolled, 217 (98·6%) were assigned an efficacy outcome and 218 (99·1%) were assessed for safety. The risk of recurrent infection was significantly higher in patients treated with quinine (70%, 74/110, HR = 3·9; 95% CI: 2·4-6·7, p<0·0001) and AL (60%, 21/35, HR = 3·3; 95% CI: 1·8-6·3, p<0·0002), compared to DHAPQ (25%, 18/72). Recrudescence tended to be lower in the DHAPQ (1%, 1/72) than in the quinine (7%, 8/110) or AL (6%, 2/35) group, though it was not statistically significant. No serious adverse events were reported.

Conclusion: Recurrent infections observed after the administration of an ACT can be successfully treated with an alternative ACT rather than with quinine.

Trial registration: Current Controlled Trials ISRCTN99046537.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Antimalarials / adverse effects
  • Antimalarials / therapeutic use*
  • Artemether
  • Artemisinins / adverse effects
  • Artemisinins / therapeutic use
  • Child, Preschool
  • Ethanolamines / adverse effects
  • Ethanolamines / therapeutic use
  • Fluorenes / adverse effects
  • Fluorenes / therapeutic use
  • Humans
  • Infant
  • Lumefantrine
  • Malaria, Falciparum / drug therapy*
  • Male
  • Quinine / adverse effects
  • Quinine / therapeutic use
  • Quinolines / adverse effects
  • Quinolines / therapeutic use
  • Safety
  • Treatment Outcome
  • Uganda


  • Antimalarials
  • Artemisinins
  • Ethanolamines
  • Fluorenes
  • Quinolines
  • dihydroartemisinin
  • piperaquine
  • Quinine
  • Artemether
  • Lumefantrine

Associated data

  • ISRCTN/ISRCTN99046537

Grant support

This investigation received financial support from the European & Developing Countries Clinical Trials Partnership Project Number NCT00393679, and from the Institute of Tropical Medicine, Antwerp, Belgium embedded in the Framework Agreement 3 DGCD-ITM 2008–2013, and labelled “Capacity Strengthening for Health Systems Research and HealthPolicy Development in Uganda. Dihydroartemisinin-piperaquine (Eurartesim) study drugs were provided free of charge by Sigma-Tau, Italy. Artemether lumefantrine was provided free of charge by the Uganda Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript